Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROVANA vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
15 mcg (2 m L) by nebulization twice daily, not to exceed 30 mcg/day.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily metabolized via glucuronidation (UGT1A1, UGT1A3, UGT1A9) and to a lesser extent by O-demethylation via CYP2D6 and CYP2E1.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 75% bound primarily to albumin and alpha-1-acid glycoprotein.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Approximately 1.9 L/kg (indicating extensive extravascular distribution).
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Inhalation: approximately 9–15% (due to lung deposition and local metabolism; oral bioavailability <2% due to first-pass effect).
Oral: 40-50%; Inhalation: 20-30%
No adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min; use with caution.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not approved for pediatric use; safety and efficacy not established for patients <18 years.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
No specific dose adjustment; monitor for adverse effects; start at low end of dosing range if renal or hepatic impairment present.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
LABAs increase the risk of asthma-related death. BROVANA is not indicated for the treatment of asthma.
No FDA black box warning.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, QT prolongation), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and use with other beta-agonists.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to arformoterol or any component of the product, or to racemic formoterol.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
No specific food interactions. Avoid caffeine or other stimulants as they may increase sympathetic side effects (e.g., tremor, tachycardia).
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, arformoterol (the active enantiomer of formoterol) caused fetal malformations (including omphalocele and skeletal abnormalities) at doses approximately 2.4 times the maximum recommended human daily inhalation dose (MRHDID) in rats, and delayed ossification at doses approximately 0.24 times MRHDID in rabbits. Use only if potential benefit justifies potential risk to fetus. First trimester: limited human data; second and third trimesters: may cause preterm labor due to beta-adrenergic receptor stimulation; monitor for uterine contractions.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
No human data on presence in breast milk, effects on breastfed infant, or milk production. Arformoterol is excreted in rat milk at concentrations similar to maternal plasma. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need for BROVANA. M/P ratio not available.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No specific dose adjustments established. Pharmacokinetic changes in pregnancy may include increased clearance (e.g., due to increased renal blood flow and metabolic enzyme induction), but no data for arformoterol. Use lowest effective dose; monitor for efficacy and adverse effects. Dose adjustments should be individualized.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Arformoterol (BROVANA) is a long-acting beta-2 agonist (LABA) indicated for maintenance treatment of COPD, not for acute exacerbations. It should not be used with other LABAs. Monitor for paradoxical bronchospasm and cardiovascular effects. Twice-daily dosing, not once-daily like some LABAs.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Use BROVANA exactly as prescribed, twice daily (morning and evening), not for sudden breathing problems.,Do not use more than the prescribed dose; overuse can increase risk of side effects.,Rinse mouth with water after each dose to reduce risk of thrush (if using via nebulizer with a mouthpiece).,Contact your healthcare provider if symptoms worsen or you need your rescue inhaler more often.,Common side effects include headache, chest pain, back pain, diarrhea, and sinusitis.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROVANA vs AEROLATE III, answered by our medical review team.
BROVANA is a Bronchodilator that works by BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROVANA and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROVANA is: 15 mcg (2 m L) by nebulization twice daily, not to exceed 30 mcg/day.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROVANA and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROVANA is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, arformoterol (the active enantiomer of formoterol) caused fetal malformations (inclu. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.